Follistatin 344 vs IGF-1 DES
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Follistatin 344
Follistatin 344 is a 344-amino acid isoform of follistatin — an endogenous glycoprotein that functions primarily as a myostatin and activin inhibitor. Myostatin (GDF-8) is the body's primary muscle growth suppressor; follistatin binds and neutralizes it with high affinity, removing this brake on muscle protein synthesis. Research and animal data show dramatic increases in muscle fiber size and strength when follistatin is elevated or myostatin is inhibited.
Full profileIGF-1 DES
IGF-1 DES (Des(1-3)IGF-1) is the naturally occurring truncated form of IGF-1, lacking the first three N-terminal amino acids (Gly-Pro-Glu). This small structural difference produces a dramatically more potent molecule: by removing the primary IGF binding protein (IGFBP-3) attachment site, IGF-1 DES circulates in free form with approximately 10x higher potency than standard IGF-1 LR3 at equivalent doses. It acts locally in tissue rather than systemically, making it the preferred form for targeted muscle hypertrophy research.
Full profile| Follistatin 344 | IGF-1 DES | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | FST-344, Follistatin isoform 344, FST | Des(1-3)IGF-1, Truncated IGF-1, DES-IGF-1 |
| Evidence | Research-stage | Research-stage |
| Dosing range | 50mcg–200mcg mcg, Once daily or every other day for 10–30 day cycles | 50mcg–150mcg mcg, 1–2x daily, preferably post-workout |
| Administration | Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis) | Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect) |
| Key side effects | Potential FSH suppression (reproductive effects in females — may affect menstrual cycle), Accelerated hair follicle cycling (Wnt pathway involvement — theoretical hair loss concern at high doses), Joint discomfort with rapid muscle tissue growth, Limited long-term human safety data | Hypoglycemia (potent insulin-like effect — have fast carbohydrates nearby), Localized muscle swelling at injection site, Jaw pain / facial bone growth at very high doses (acromegaly-like — dose-dependent), Organ enlargement at excessive doses |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: Follistatin 344 — Subcutaneous injection, Intramuscular injection (into target muscle — local effect hypothesis); IGF-1 DES — Subcutaneous injection, Intramuscular injection (into target muscle for local hypertrophic effect).
- Frequency: Follistatin 344 is typically Once daily or every other day for 10–30 day cycles; IGF-1 DES is 1–2x daily, preferably post-workout.
- Research depth: this profile cites 3 sources for Follistatin 344 vs 2 for IGF-1 DES.
How each works
Follistatin 344
Follistatin's muscle effects were dramatically illustrated when mice and cattle with follistatin overexpression or myostatin knockouts developed 2–3x normal muscle mass. Human follistatin gene therapy trials (AAV-mediated) are ongoing for Becker Muscular Dystrophy, showing sustained myostatin inhibition and improved muscle function over years from a single injection. Follistatin also inhibits activin A and B (involved in muscle wasting during illness), FSH secretion (reproductive effects), and inflammatory cytokines. The 344 isoform has an extended heparin-binding domain that increases tissue retention compared to the shorter FST-288 isoform.
IGF-1 DES
The three N-terminal amino acids of IGF-1 are the primary binding site for IGFBP-3 (IGF binding protein 3), which sequesters 75–90% of circulating IGF-1 in an inactive bound form. IGF-1 DES lacks this binding site, meaning virtually all injected peptide reaches tissue receptors as free (active) IGF-1. In skeletal muscle research, Des-IGF-1 promotes satellite cell activation, myoblast proliferation, and differentiation at lower doses than LR3. It has a shorter half-life (~20–30 minutes) than LR3 but acts more intensely — particularly at the site of injection.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.